Impact of clinical features on the efficacy of osimertinib treatment in epidermal growth factor receptor mutant non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors due to T790M mutation

被引：0
作者：
Liam, Chong-Kin [1 ]
Poh, Mau-Ern [1 ]
Liam, Yong-Sheng [2 ]
机构：
[1] Univ Malaya, Fac Med, Dept Med, Kuala Lumpur 50603, Malaysia
[2] Univ Malaya, Clin Invest Ctr, Med Ctr, Kuala Lumpur, Malaysia
来源：
JOURNAL OF THORACIC DISEASE | 2019年 / 11卷
关键词：
OPEN-LABEL; EGFR-TKI; THERAPY;
D O I：
10.21037/jtd.2019.08.117
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：S1847 / S1851
页数：5
相关论文
共 25 条
  • [1] Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial
    Akamatsu, Hiroaki
    Katakami, Nobuyuki
    Okamoto, Isamu
    Kato, Terufumi
    Kim, Young Hak
    Imamura, Fumio
    Shinkai, Masaharu
    Hodge, Rachel A.
    Uchida, Hirohiko
    Hida, Toyoaki
    [J]. CANCER SCIENCE, 2018, 109 (06): : 1930 - 1938
  • [2] High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer
    Ariyasu, Ryo
    Nishikawa, Shingo
    Uchibori, Ken
    Oh-hara, Tomoko
    Yoshizawa, Takahiro
    Dotsu, Yosuke
    Koyama, Junji
    Saiki, Masafumi
    Sonoda, Tomoaki
    Kitazono, Satoru
    Yanagitani, Noriko
    Horiike, Atsushi
    Inase, Naohiko
    Kasahara, Kazuo
    Nishio, Makoto
    Katayama, Ryohei
    [J]. LUNG CANCER, 2018, 117 : 1 - 6
  • [3] Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation
    Auliac, Jean Bernard
    Perol, Maurice
    Planchard, David
    Monnet, Isabelle
    Wislez, Marie
    Doubre, Helene
    Guisier, Florian
    Pichon, Eric
    Greillier, Laurent
    Mastroianni, Benedicte
    Decroisette, Chantal
    Schott, Roland
    Le Moulec, Sylvestre
    Arrondeau, Jennifer
    Cortot, Alexis B.
    Geriniere, Laurence
    Renault, Aldo
    Daniel, Catherine
    Falchero, Lionel
    Chouaid, Christos
    [J]. LUNG CANCER, 2019, 127 : 96 - 102
  • [4] AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
    Cross, Darren A. E.
    Ashton, Susan E.
    Ghiorghiu, Serban
    Eberlein, Cath
    Nebhan, Caroline A.
    Spitzler, Paula J.
    Orme, Jonathon P.
    Finlay, M. Raymond V.
    Ward, Richard A.
    Mellor, Martine J.
    Hughes, Gareth
    Rahi, Amar
    Jacobs, Vivien N.
    Brewer, Monica Red
    Ichihara, Eiki
    Sun, Jing
    Jin, Hailing
    Ballard, Peter
    Al-Kadhimi, Katherine
    Rowlinson, Rachel
    Klinowska, Teresa
    Richmond, Graham H. P.
    Cantarini, Mireille
    Kim, Dong-Wan
    Ranson, Malcolm R.
    Pao, William
    [J]. CANCER DISCOVERY, 2014, 4 (09) : 1046 - 1061
  • [5] Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
    Goss, Glenwood
    Tsai, Chun-Ming
    Shepherd, Frances A.
    Bazhenova, Lyudmila
    Lee, Jong Seok
    Chang, Gee-Chen
    Crino, Lucio
    Satouchi, Miyako
    Chu, Quincy
    Hida, Toyoaki
    Han, Ji-Youn
    Juan, Oscar
    Dunphy, Frank
    Nishio, Makoto
    Kang, Jin-Hyoung
    Majem, Margarita
    Mann, Helen
    Cantarini, Mireille
    Ghiorghiu, Serban
    Mitsudomi, Tetsuya
    [J]. LANCET ONCOLOGY, 2016, 17 (12) : 1643 - 1652
  • [6] A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC)
    Goto, Koichi
    Nishio, Makoto
    Yamamoto, Noboru
    Chikamori, Kenichi
    Hida, Toyoaki
    Maemondo, Makoto
    Katakami, Nobuyuki
    Kozuki, Toshiyuki
    Yoshioka, Hiroshige
    Seto, Takashi
    Fukuyama, Tamaki
    Tamura, Tomohide
    [J]. LUNG CANCER, 2013, 82 (01) : 109 - 114
  • [7] Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study
    Igawa, Satoshi
    Ono, Taihei
    Kasajima, Masashi
    Ishihara, Mikiko
    Hiyoshi, Yasuhiro
    Kusuhara, Seiichiro
    Nishinarita, Noriko
    Fukui, Tomoya
    Kubota, Masaru
    Sasaki, Jiichiro
    Hisashi, Mitsufuji
    Yokoba, Masanori
    Katagiri, Masato
    Naoki, Katsuhiko
    [J]. CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 4883 - 4892
  • [8] Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
    Jain, Amit
    Lim, Cindy
    Gan, Eugene MingJin
    Ng, David Zhihao
    Ng, Quan Sing
    Ang, Mei Kim
    Takano, Angela
    Chan, Kian Sing
    Tan, Wu Meng
    Kanesvaran, Ravindran
    Toh, Chee Keong
    Loo, Chian Min
    Hsu, Anne Ann Ling
    Devanand, Anantham
    Lim, Chong Hee
    Koong, Heng Nung
    Koh, Tina
    Fong, Kam Weng
    Yap, Swee Peng
    Kim, Su Woon
    Chowbay, Balram
    Oon, Lynette
    Lim, Kiat Hon
    Lim, Wan Teck
    Tan, Eng Huat
    Tan, Daniel Shao Weng
    [J]. PLOS ONE, 2015, 10 (05):
  • [9] Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors
    Kato, Yasuhiro
    Hosomi, Yukio
    Watanabe, Kageaki
    Yomota, Makiko
    Kawai, Shoko
    Okuma, Yusuke
    Kubota, Kaoru
    Seike, Masahiro
    Gemma, Akihiko
    Okamura, Tatsuru
    [J]. JOURNAL OF THORACIC DISEASE, 2019, 11 (06) : 2350 - 2360
  • [10] Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma
    Lohinai, Zoltan
    Hoda, Mir Alireza
    Fabian, Katalin
    Ostoros, Gyula
    Raso, Erzsebet
    Barbai, Tamas
    Timar, Jozsef
    Kovalszky, Ilona
    Cserepes, Mihaly
    Rozsas, Anita
    Laszlo, Viktoria
    Grusch, Michael
    Berger, Walter
    Klepetko, Walter
    Moldvay, Judit
    Dome, Balazs
    Hegedus, Balazs
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (05) : 738 - 746
123